Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Literature DB >> 16495273

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Longzhu Cui¹, Eiji Tominaga, Hui-Min Neoh, Keiichi Hiramatsu.

Abstract

We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA). This correlation is related to cell wall thickening, suggesting that, similar to the case with vancomycin resistance in VISA, the physical barrier of a thickened cell wall may contribute to daptomycin resistance in S. aureus.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 16495273 PMCID： PMC1426436 DOI： 10.1128/AAC.50.3.1079-1082.2006

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

19 in total

1. Has vancomycin-resistant Staphylococcus aureus started going it alone?

Authors: Keiichi Hiramatsu; Longzhu Cui; Kyoko Kuwahara-Arai
Journal: Lancet Date: 2004 Aug 14-20 Impact factor: 79.321

2. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors: K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal: Lancet Date: 1997-12-06 Impact factor: 79.321

3. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors: K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal: J Antimicrob Chemother Date: 1997-07 Impact factor: 5.790

4. Daptomycin: a novel agent for Gram-positive infections.

Authors: F P Tally; M Zeckel; M M Wasilewski; C Carini; C L Berman; G L Drusano; F B Oleson
Journal: Expert Opin Investig Drugs Date: 1999-08 Impact factor: 6.206

Review 5. The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors: K Hiramatsu; L Cui; M Kuroda; T Ito
Journal: Trends Microbiol Date: 2001-10 Impact factor: 17.079

6. Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors: Raymond Cha; Richard G Grucz; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191

7. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors: A Mangili; I Bica; D R Snydman; D H Hamer
Journal: Clin Infect Dis Date: 2005-02-17 Impact factor: 9.079

Review 8. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors: K Hiramatsu
Journal: Lancet Infect Dis Date: 2001-10 Impact factor: 25.071

9. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.

Authors: Valerie Laganas; Jeffrey Alder; Jared A Silverman
Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191

10. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors: Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal: J Clin Microbiol Date: 2003-01 Impact factor: 5.948

145 in total

1. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors: Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal: J Bacteriol Date: 2012-06-01 Impact factor: 3.490

2. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors: Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2010-02-16 Impact factor: 5.191

3. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors: Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal: Antimicrob Agents Chemother Date: 2010-10-25 Impact factor: 5.191

4. Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.

Authors: Chen-Hsiang Lee; Ming-Chung Wang; I-Wen Huang; Feng-Jui Chen; Tsai-Ling Lauderdale
Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191

5. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors: Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal: Haematologica Date: 2013-12 Impact factor: 9.941

6. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors: Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal: Int J Antimicrob Agents Date: 2009-02-23 Impact factor: 5.283

7. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors: Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2007-11-12 Impact factor: 5.191

8. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors: Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal: Antimicrob Agents Chemother Date: 2013-11-11 Impact factor: 5.191

Review 9. A current perspective on daptomycin for the clinical microbiologist.

Authors: Romney M Humphries; Simon Pollett; George Sakoulas
Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132

Review 10. Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus.

Authors: Adriana Renzoni; William L Kelley; Pierre Vaudaux; Ambrose L Cheung; Daniel P Lew
Journal: Trends Microbiol Date: 2009-12-11 Impact factor: 17.079